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Chronic rejection of mouse kidney allografts. of acute rejection are a major risk factor for the develop-
Background. Chronic renal allograft rejection is the leading ment of chronic rejection [3], the observations that strin-
cause of late graft failure. However, its pathogenesis has not gent HLA-matching is protective, and that inadequatebeen defined.
immunosuppression is associated with the developmentMethods. To explore the pathogenesis of chronic rejection,
of chronic rejection. Nonimmunological factors suggestedwe studied a mouse model of kidney transplantation and exam-
ined the effects of altering the expression of donor major histo- to play a role include glomerular hyperfiltration, ische-
compatibility complex (MHC) antigens on the development of mia-reperfusion injury, and uncontrolled hypertension
chronic rejection. [4]. Although there have been a number of recent ad-Results. We found that long-surviving mouse kidney allografts
vances in the prevention and treatment of acute allograftdevelop pathological abnormalities that resemble chronic re-
jection in humans. Furthermore, the absence of MHC class I rejection, little progress has been made in developing
or class II antigens did not prevent the loss of graft function therapies for chronic rejection. In kidney transplants,
nor alter the pathological characteristics of chronic rejection. chronic rejection is the leading cause of late graft failure.
Expression of transforming growth factor-b (TGF-b), a pleio-
The immunological component underlying chronic re-tropic cytokine suggested to play a role in chronic rejection, was
jection must be triggered at some level by the recognitionmarkedly enhanced in control allografts compared with isografts.
However, TGF-b up-regulation was significantly blunted in of major histocompatibility complex (MHC) alloantigens
MHC-deficient grafts. Nonetheless, these differences in TGF-b by recipient T cells. In general, allorecognition may occur
expression did not affect the character of chronic rejection, through two pathways. The first is through direct recogni-including intrarenal accumulation of collagens.
tion of MHC alloantigens on donor cells by recipient TConclusions. Reduced expression of either class I or II direct
cells. The second is through indirect recognition, in whichallorecognition pathways is insufficient to prevent the develop-
ment of chronic rejection, despite a reduction in the levels of donor MHC alloantigens are taken up, processed, and
TGF-b expressed in the allograft. This suggests that the severity presented to recipient T cells as peptides in the context
of chronic rejection is independent of the level of MHC dispar-
of recipient MHC. A key role for allorecognition andity between donor and recipient and the level of TGF-b expres-
T-cell activation in the pathogenesis of chronic rejectionsion within the allograft.
is suggested by studies in which blockade of T-cell co-
stimulatory signals with CTLA4Ig ameliorates chronic re-
jection [5, 6]. However, the relative contribution of theChronic rejection of a kidney transplant is character-
direct versus indirect pathways in the pathogenesis ofized by a progressive loss of renal function associated
chronic rejection has not been defined.with arteriosclerosis, interstitial fibrosis, tubular atrophy,
Regardless of how alloantigen is recognized, severaland glomerular sclerosis. Although the pathogenesis of
chronic rejection is not well characterized, both immuno- immune effector systems have been implicated in chronic
logical and nonimmunological mechanisms may be in- rejection, including antibodies, complement, and various
volved [1, 2]. A role for immunological factors is sug- cytokines. Because of its ability to regulate immune re-
gested by clinical studies showing that previous episodes sponses and extracellular matrix production, several
studies have focused on a possible role for transforming
growth factor-b (TGF-b) in this process. There are sev-Key words: transplantation, renal graft rejection, TGF-b, fibrosis,
mouse MHC, arteriosclerosis, glomerulosclerosis. eral lines of evidence suggesting that TGF-b may partici-
pate in graft rejection. For example, urinary levels ofReceived for publication June 11, 1998
TGF-b are increased in kidney transplant recipients [7,and in revised form October 15, 1998
Accepted for publication December 1, 1998 8], and during acute and chronic rejection in humans,
TGF-b expression is enhanced in kidney grafts [9]. En- 1999 by the International Society of Nephrology
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hanced TGF-b gene expression has also been demon- Measurement of kidney transplant function
strated within rejecting cardiac allografts [10, 11]. Al- To assess kidney transplant function accurately, clear-
though some of its biological effects might promote graft ances of inulin and paraaminohippuric acid (PAH) were
injury in rejection, TGF-b may also act to suppress im- measured as previously described [16]. Clearances of
mune responses. In murine models, the administration carboxyl-14C-inulin and glycyl-3H-PAH were used as mea-
of TGF-b prolonged survival of cardiac allografts [12, sures of glomerular filtration rate (GFR) and renal plasma
13]. Thus, although TGF-b expression may be enhanced flow, respectively. Six isografts, four control allografts,
in rejecting grafts, its role in the pathogenesis of chronic and three class I2 and four class II2 kidney allografts
allograft rejection remains unclear. were studied.
In this article, we examine the effects of altering ex-
Histopathologypression of donor alloantigens in a mouse model of
chronic rejection. We find that in the absence of either Following the clearance study, a portion of each graft
was placed in formalin and stained with hematoxylin-MHC class I or class II antigens, TGF-b production is
eosin and Masson’s trichrome. The sections were evalu-reduced in the graft, but the course and severity of
ated by a renal pathologist (P.R.) who was masked to thechronic rejection are unchanged. Thus, reduction of anti-
experimental groups. Sections were graded for overallgen density on the donor graft does not prevent the
severity of histopathological abnormalities using a semi-development of chronic rejection. Although a reduced
quantitative scale as we have previously described [17].level of donor alloantigens results in reduced expression
The severity of chronic interstitial, tubular, vascular, andof TGF-b, this decrease in intragraft TGF-b is not suffi-
glomerular changes was graded separately using a semi-cient to alter the course of chronic rejection in this model.
quantitative scale, in which 0 was no abnormality and 1,
2, 3, and 4 represented mild, moderate, moderately severe,
METHODS and severe abnormalities, respectively. These changes
included focal glomerular hypercellularity, membranousAnimals
thickening, focal, segmental mesangial expansion, chronicFor the control allografts, [C57BL/6 J 3129/J]F1 (H-2b) inflammation, tubular dilation and casts, fibrosis, andmice were bred in the Durham VA Animal Facility and
perivascular fibrosis. An overall histological score wasused as donors. To examine the effects of donor MHC
obtained by summing these individual values.expression on chronic rejection, class II-deficient mice
(class II2; H-2b) [14] or class I-deficient mice (class I2; Immunohistology
H-2b) [15] were used as kidney donors. [BALB/c 3 DBA/
Immunopathology was performed as previously de-
2 J]F1 (H-2d) mice were purchased from Jackson Labora- scribed [18]. Briefly, kidney tissue was embedded in OCT
tory (Bar Harbor, ME, USA) and were used as recipients
compound and snap frozen in precooled 2-methylbutane.
of kidney grafts in all of the experiments. As nonrejecting
Tissue sections (4 mm) were cut with a cryostat, air dried,
isograft controls, kidneys from [BALB/c 3 DBA/2 J]F1 and fixed in acetone. Fixed sections were washed with
mice were transplanted into their littermates. phosphate-buffered saline (pH 7.4), blocked with normal
mouse serum, and stained with appropriately dilutedMouse kidney transplantation
primary monoclonal antibody. Binding of the primary
Vascularized kidney transplants were performed in antibody was detected with affinity-purified fluorescein
mice as previously described [16]. Briefly, animals were isothiocyanate-labeled goat antirat IgG, followed by a
anesthetized with isoflurane, and the donor kidney, ureter, secondary layer of affinity-isolated fluorescein isothiocy-
and bladder were harvested en bloc, including the renal anate-rabbit antigoat IgG (Cappel, Durham, NC, USA).
artery with a small aortic cuff and the renal vein with a The primary rat monoclonal antibodies used included
small caval cuff. These vascular cuffs were anastomosed TIB126 (anti-class I), TIB120 (anti-class II), GK1.5 (anti-
to the recipient abdominal aorta and vena cava, respec- CD4), and 3.155 (anti-CD8), prepared as hybridoma su-
tively, below the level of the native renal vessels. Total pernatants (American Type Culture Collection, Rock-
ischemic time averaged 35 to 40 minutes. Donor and ville, MD, USA), 30-H122 (anti-Thy 1.2; Boehringer
recipient bladders were attached dome to dome. The Mannheim, Indianapolis, IN, USA), RA36B2 (anti-
right native kidney was removed at the time of trans- B220), and M1/70HL (anti-CD11b/Mac-1; Pharmingen,
plant, and the left native kidney was removed through San Diego, CA, USA).
a flank incision four days later. Overall surgical mortality
Quantitative immunohistologywas approximately 40%, and there were no significant
differences in perioperative mortality between the exper- Quantitative immunohistology was performed as pre-
viously described [19, 20]. Cells were quantitated usingimental groups.
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a 1 cm2 grid divided into 100 1 mm2 squares placed in the (DMSO), as previously described [21]. RNA samples were
dried briefly, resuspended in 10 ml of glyoxal/DMSO solu-eyepiece of a Leitz DMRB microscope (Leica, Berlin,
Germany). Cells were counted in 10 randomly selected tion (50% DMSO, 1.2 m deionized glyoxal, 20 mm sodium
phosphate, pH 6.8), and incubated at 508C for one hour.squares and were scored with the 340 objective. Final
counts were expressed as the number of cells per square The samples were cooled on ice, loaded with 2.5 ml of
gel loading buffer (36% sucrose, 0.07% xylene cyanol,mm (mean 6 sem). All sections were evaluated by an
individual who was masked to the experimental groups. 0.07% bromphenol blue), and run on a 1.2% agarose
gels in recirculating 10 mm sodium phosphate buffer,
Immunohistology of transforming growth pH 6.8. The gels were blotted onto a nylon membrane
factor-b1, -b2 and collagens (Hybond-N; Amersham, Arlington Heights, IL, USA),
Tissue was fixed in neutral-buffered formalin or meth- exposed to long-wave ultraviolet light for three minutes,
acarn (methanol Carnoy’s solution). At four weeks, five and baked for two hours at 808C. Hybridization was
isografts, five control allografts, and three class I2 and performed at 428C overnight with a full-length rat cDNA
three class II2 allografts were stained and analyzed. For for TGF-b1 [22] and mouse cDNA for TGF-b3 (obtained
TGF-b localization, paraffin sections from tissues fixed in from S.W. Qian, NCI, NIH) labeled with 32P by the ran-
formalin or methacarn were digested with hyaluronidase dom primer method (Boehringer Mannheim). Following
(Sigma, St. Louis, MO, USA) and subjected to immuno- the overnight hybridization, the filters were washed four
staining using the Histostain kit (Zymed, Burlingame, times with 2 3 standard saline citrate (SSC)/0.1% sodium
CA, USA) using the directions supplied. The first anti- dodecyl sulfate (SDS) for 20 minutes at room tempera-
body, rabbit anti-TGF-b1 peptide [CC antibody; a gift of ture, then washed once with 0.1 3 SSC/0.1% SDS for
Dr. Kathleen Flanders, National Cancer Institute (NCI), 30 minutes at 558C. Filters were exposed to film (Kodak
NIH, Bethesda, MD, USA] was applied at 2 mg/ml over- X-OMAT, Rochester, NY, USA) for up to one week at
night at 48C. This antibody recognized both TGF-b1 and 2808C. The filters were later stripped and rehybridized
TGF-b2 within the extracellular matrix. For collagen with a 32P-labeled b-actin cDNA using conditions as de-
staining, methacarn-fixed tissue sections were digested scribed earlier here. The intensity of the signals on auto-
with pronase. Biotinylated goat antibodies directed radiograms was quantitated by laser densitometry, and
against collagen I and III (Southern Biotechnology Asso- the results are expressed as arbitrary densitometry units
ciates, Birmingham, AL, USA) were used at a dilution that correspond to the area under the densitometric peak.
of 5 mg/ml for 60 minutes at 378C; for these antibodies,
Statistical analysisthe normal serum block and the second antibody were
omitted. Rabbit-anticollagen IV antiserum (a gift of Dr. Data are presented as the mean 6 standard error of
the mean. For the hemodynamic studies, the mean ofHynda Kleinman, NIDR, NIH) was used at a dilution
of 1:100 for 60 minutes at 378C. Negative controls for two clearance periods is given. Statistical significance was
assessed using the Student’s t-test or Wilcoxon rank sumthe first antibody included normal rabbit IgG (Zymed),
normal rabbit serum (Life Technologies, Rockville, MD, test as appropriate, except for immunohistochemistry
scores, which were analyzed by analysis of variance usingUSA), and biotinylated goat antihuman Ig antibody
(Zymed). These gave negligible staining. the Instat program (GraphPad, San Diego, CA, USA).
The stained sections were evaluated by observers
masked to the identity of the experimental groups. For RESULTS
TGF-b, the scale included: 0 5 absent or present only
Glomerular filtration rate is reduced in long-survivingwithin the renal capsule; 0.5 5 trace staining within the
mouse kidney allograftsinterstitium; 1 5 limited focal interstitial staining; 2 5
We first evaluated whether mouse kidney allograftswidespread focal interstitial staining; and 3 5 widespread
that survive for prolonged periods relative to skin orstaining. For collagens I, III, and IV, the extent of staining
cardiac allografts [16, 17, 23] develop clinical features ofwas rated in a similar fashion, with 0 5 absent; 0.5 5
chronic rejection. To assess the physiological functiontrace staining; 1 5 mild increase in staining; 2 5 moderate
of these allografts, we performed renal hemodynamicincrease in staining; and 3 5 considerable increase in
measurements. Figure 1 shows GFR measured in trans-staining.
planted kidneys six weeks following transplantation.
RNA isolation and analysis GFR in isografts (6.1 6 0.7 ml/min/kg) was similar to
levels seen in normal mice following uninephrectomyTotal cellular RNA was isolated from kidneys follow-
[24]. Compared with the isografts, GFR was significantlying clearance studies using the guanidinium isothiocya-
nate method [21]. Expression of TGF-b1 and TGF-b3 reduced in allograft kidneys (2.6 6 0.7 ml/min/kg, P 5
0.008). Thus, six weeks following transplantation, renalmRNA was determined by Northern blot. Fifteen micro-
grams of RNA were sized fractionated on agarose gels, function in mouse kidney allografts was markedly de-
pressed compared with nonrejecting isografts.after denaturation by glyoxal and dimethyl sulfoxide
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1.5 in allografts (P , 0.005). Thus, by six weeks after
transplantation, mouse kidney allografts have reduced
renal function and exhibit many of the histological fea-
tures seen in chronic rejection of human kidney allografts.
Chronic rejection is also seen in allografts from
multiple histocompatibility complex deficient donors
To determine whether altering the potential for direct
recognition of donor alloantigens might affect the char-
acteristics of chronic rejection, kidneys from MHC class
I2 or MHC class II2 donors (H-2b) were transplanted
into MHC-disparate (H-2d) recipients. GFR measured
in recipients of MHC-deficient grafts six weeks after trans-
plantation is shown in Figure 1. The GFR in MHC class
I2 (2.6 6 0.4 ml/min/kg) and MHC class II2 (3.8 6
1.4 ml/min/kg) allografts were not significantly different
from that of control allografts (2.6 6 0.7 ml/min/kg).
Although the level of GFR was somewhat higher in class
II2 allografts compared with the other allograft groups,
Fig. 1. Renal function six weeks following transplantation measured this difference was not statistically significant. Histologi-
in isografts (h), allografts (j), MHC class I2 ( ), and MHC class II2
cal abnormalities in MHC class I2 (Fig. 2c) and MHC( ) allografts. GFR in the experimental groups is expressed in ml/min/
kg. GFR was significantly reduced in allografts (*P 5 0.008) and MHC class II2 (Fig. 2d) allografts were similar qualitatively to
class I– allografts (**P 5 0.01) compared with nonrejecting isografts. those seen in control allografts. Like the control allo-
grafts, MHC-deficient grafts exhibited extensive intersti-
tial fibrosis, tubular atrophy, perivascular and medial
fibrosis, and significant glomerular abnormalities. Addi-Kidney allografts have histological features of
tionally, the mean histological scores of MHC class I2chronic rejection
(14.6 6 2.0) and MHC class II2 allografts (12.1 6 3.8)
To determine whether the reduction in GFR was ac- were not significantly different from the scores of control
companied by histological abnormalities suggesting
allografts (14.4 6 1.5). Thus, the absence of normal ex-
chronic rejection, we examined the kidney grafts by light
pression of either MHC class I or class II antigens on themicroscopy. Only minor histological abnormalities were
kidney graft did not prevent a loss of graft function norappreciated in kidney isografts (Fig. 2a), principally con-
alter the pathological characteristics of chronic rejection.sisting of mild membranous thickening of the peripheral
glomerular capillary loops and focal mesangial hypercel- Immunohistochemical analysis of allograft infiltrates
lularity within the glomeruli. No significant interstitial
Significant infiltration by inflammatory cells was pres-fibrosis or vascular abnormalities were evident in the
ent in all of the allograft groups. To characterize theseisografts. By comparison, the control kidney allografts
immune cell infiltrates, morphometric analysis was per-revealed marked histopathological alterations, as de-
formed on sections of kidney grafts stained with mono-picted in Figure 2b. For example, allografts contained
clonal antibodies against T cell and macrophage markers.an increase in glomerular mesangial and endocapillary
The results of these analyses are shown in Figure 3.cell hyperplasia, with membranous thickening of the cap-
Similar numbers of CD41 T cells infiltrating the graftsillary loops and marked periglomerular fibrosis. Exten-
were seen in each group. However, the number of CD81sive interstitial fibrosis, a hallmark of chronic rejection
T cells was significantly reduced in the MHC class I2in humans, was also present. Control allografts also con-
allografts (40 6 4 cells/mm2) compared with controls (59 6tained diffuse and patchy chronic inflammatory cell infil-
6 cells/mm2, P 5 0.05) and MHC class II2 allograftstrates accompanied by significant tubular dilation and
(82 6 10 cells/mm2, P 5 0.008). Although the numberatrophy. Finally, there were notable vascular alterations
of macrophages tended to be higher in control comparedin the allografts exemplified by perivascular and medial
with MHC-deficient allografts, this difference was notfibrosis, although significant intimal proliferation was not
statistically significant. Thus, despite the similar histolog-seen. Semiquantitative grading of the isografts and allo-
ical appearance of chronic rejection in the allograftgrafts was performed to estimate the severity of these
groups, the absence of class I alloantigens on the donorhistopathological abnormalities, with cumulative scores
was associated with a significant reduction in the numberbeing generated for the individual organs. In isografts,
the mean score was 4.9 6 0.4 compared with 14.4 6 of CD81-infiltrating cells.
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Fig. 2. Masson’s trichrome-stained sections of transplanted kidneys six weeks following transplantation. Relatively normal architecture was seen
in nonrejecting isografts (a). Marked histological abnormalities consistent with chronic rejection are seen in allografted kidneys as described in
the text (b). In MHC class I– (c) and class II2 allografts (d), changes characteristic of chronic rejection were seen, and the scope and severity were
similar to control allografts (magnification 3100). Reproduction of this figure in color was supported by a grant from Roche Pharmaceuticals.
Transforming growth factor-b immunostaining in tively, TGF-b staining was significantly increased in allo-
mouse kidney grafts grafts compared with the negligible staining seen in iso-
grafts (2.0 6 0.4 vs. 0.4 6 0.1, P 5 0.006). To determineBecause of its ability to modulate immune responses
whether or not altered expression of donor MHC anti-and extracellular matrix protein production, TGF-b has
gens might affect this response, TGF-b immunostainingbeen suggested to be a causative factor in the pathogene-
was also performed in allografts from MHC-deficientsis of chronic transplant rejection [9]. Therefore, we ex-
donors (Fig. 4c). Although the distribution of TGF-bamined TGF-b expression in mouse kidney grafts. By
staining in MHC-deficient grafts was similar to controls,four weeks after transplantation, intense TGF-b staining
the relative intensity of staining was markedly reducedwas present within the interstitium and particularly
(1.3 6 0.3 for class I2 allografts, 0.5 6 0.1 for class II2around small arteries of control allografts (Fig. 4b). This
allografts, P 5 0.04 compared with allograft controls).staining in allografts was often localized to infiltrating
These differences in intragraft TGF-b were transient,cells rather than surrounding tubules. In contrast, as
and by six weeks after transplantation, TGF-b stainingshown in Figure 4a, only trace amounts of staining for
TGF-b were seen in isografts. When analyzed quantita- was negligible in all of the experimental groups.
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blood vessels (Fig. 6a). Collagen III staining was in-
creased in both control (Fig. 6b) and MHC class II2
allografts (Fig. 6c), especially within the cortical intersti-
tium and around small- and medium-sized arterioles. As
shown in Table 2, this was reflected by a 3.8-fold increase
in the quantitative analysis of collagen III staining in
control allografts compared with isografts (P 5 0.01)
and a 4.3-fold increase in staining in the MHC class II2
allografts compared with isografts (P , 0.001). Collagen
I staining was also significantly increased in both control
(ninefold, P 5 0.01) and MHC class II2 allografts (10-
fold, P , 0.001) compared with isografts (Table 2). In
the control and class II2 allografts, increases in the inten-
sity of staining in the cortical and medullary interstitium
were observed (data not shown). Collagen IV staining
was observed in the basement membranes of the glomer-
uli, tubules, blood vessels, and glomerular mesangium inFig. 3. Morphometric analysis of graft-infiltrating lymphocytes. Sec-
tions of kidney grafts were stained and quantitatively analyzed by immu- isografts (data not shown). Similarly, collagen IV in con-
nofluorescence as described in the Methods section. Allografts ( ), trol and class II2 allografts was present in normal amounts
MHC class I2 allografts ( ), and class II2 allografts ( ) are shown.
in basement membrane, but was modestly increasedNo infiltrating cells were detected in isografts. There were no differences
in the numbers of CD41 T cells infiltrating the allografts. However, the within the glomerular mesangium (data not shown).
number of CD81 T cells was significantly reduced in MHC class I2
allografts compared with controls and MHC class II2 allografts (*P 5
0.05 and P 5 0.008, respectively). The number of macrophages was DISCUSSION
reduced in MHC-deficient grafts compared with controls, but this was
not significant. Chronic rejection is a common complication of suc-
cessful kidney transplantation in humans. The character-
istic clinical picture of chronic renal allograft rejection
consists of a progressive decline in GFR, often associated
Transforming growth factor-b mRNA expression in with proteinuria. Although this entity is the leading cause
mouse kidney grafts of late kidney graft failure, its pathogenesis is not well
To determine whether differences in intragraft TGF-b characterized, and there are no effective treatments once
protein accumulation were associated with alterations in these particular lesions have developed. To better under-
intragraft levels of TGF-b mRNA, we assessed mRNA stand the mechanisms contributing to the development
levels of TGF-b1 and TGF-b3 by Northern blot analysis of chronic rejection, various animal models have been
four weeks following transplantation. As shown in Figure used. These include accelerated arteriosclerosis in mouse
5, TGF-b mRNA levels generally correlated with protein carotid artery loops transplanted onto the carotid artery
levels. Expression of TGF-b1 and TGF-b3 mRNA in of a histoincompatible recipient [25], coronary arterio-
control allografts was increased 3.3-fold and 6.6-fold, sclerosis in vascularized mouse [26] and rat hearts [27],
respectively, compared with isografts (Table 1). TGF- and chronic rejection in F344 3 LEW kidney allografts
b1 and TGF-b3 mRNA levels in MHC class II2 allografts [28]. In this report, we have documented the develop-
were modestly reduced compared with control allografts ment of chronic rejection in a mouse model of kidney
(2.1-fold and 5.8-fold increase in expression, respec- transplantation. These mouse renal allografts develop a
tively, compared with isografts). Similar results were number of features that are observed in chronic rejection
seen with MHC class I2 grafts (data not shown). Al- in human kidney grafts, including interstitial fibrosis and
though these differences in mRNA levels between trans- glomerulosclerosis. This model therefore provides a sys-
plant groups were substantial, they did not reach statisti- tem for studying the mechanisms of kidney injury in
cal significance. chronic rejection, and we have used it to examine the
role of altering donor MHC antigen expression on the
Accumulation of collagen in mouse kidney allografts character of chronic rejection.
Interstitial fibrosis and glomerular sclerosis are two of The triggering stimulus for alloimmune responses, in-
the defining features of chronic rejection. To evaluate cluding those that lead to chronic rejection, is the recog-
the nature of the abnormal extracellular matrix in these nition of alloantigens from the donor organ by T cells
kidneys, we performed immunoperoxidase staining for of the recipient. Direct recognition of alloantigens, in
collagens type I, III (Fig. 6), and IV. In isografts, collagen which donor MHC antigens are directly recognized by
the antigen receptor on recipient T cells, has been sug-III was present in trace amounts in areas adjacent to
Mannon et al: Chronic rejection of mouse kidney allografts 1941
gested to contribute to the intensity and high precursor with glomerular injury [30], and a number of studies
have suggested that TGF-b may play a similar role infrequency of alloimmune responses and may be most
chronic rejection [7, 9, 10]. In particular, the effects ofimportant in initiating acute allograft rejection [5, 6]. In
TGF-b to stimulate extracellular matrix production andcontrast, the indirect pathway for allorecognition has
deposition may be a key component in the pathogenesisbeen implicated in the pathogenesis of chronic rejection
of chronic kidney injury [30, 31]. In comparing the con-[29]. In previous studies, we demonstrated that kidney
trol and MHC-deficient allografts, we find that the inten-grafts from donor mice lacking class I MHC expression
sity of TGF-b expression within the grafts is dissociatedhave relatively well-preserved renal function during the
from the development of chronic injury and, specifically,early weeks following transplantation, despite histologi-
with abnormal deposition of collagen chains in the renal
cal changes characteristic of acute rejection [16]. Kidney interstitium. Thus, despite the reduced levels of TGF-b
grafts from donors lacking MHC class II antigens also found in MHC-deficient grafts, the severity of kidney
maintained GFR and demonstrated an infiltrating cell injury and the enhancement of collagen deposition in
population with a relative deficiency of CD41 T cells these grafts are virtually identical to controls. This could
(abstract; Mannon et al, J Am Soc Nephrol 5:984, 1994). be due to altered receptor expression for TGF-b within
In contrast, allografts from MHC-deficient donors de- the experimental groups. Alternatively, factors other
velop pathological changes of chronic rejection of the than TGF-b may contribute to the development intersti-
same severity as allografts from mice with normal MHC tial and perivascular fibrosis in this model. These might
antigen expression. The occurrence of chronic rejection, include other fibrogenic growth factors and cytokines,
such as fibroblast growth factor [11, 32] and platelet-despite a dramatic decrease of donor MHC antigen ex-
derived growth factor [33, 34], insulin-like growth factorpression, suggests that only a threshold level of antigen
[35], interleukin-6 [36], connective tissue growth factorstimulation may be required to initiate these lesions.
[37], or vasoactive factors such as inducible nitric oxideAlternatively, the mechanisms leading to chronic rejec-
synthase [38, 39]. Finally, the role of TGF-b in this modeltion in this model may be relatively insensitive to a re-
may be complex and may not depend on a sustainedduced capacity for allorecognition. As significant and
intrarenal elevation of TGF-b production.equivalent numbers of CD41 cells are seen in both MHC-
The mouse model that we describe here has a numberdeficient groups, these cells may also play a role in the
of features that are similar to chronic rejection in hu-
pathogenesis of this disorder. mans. However, there are also some important differ-
Although altered expression of donor alloantigens did ences. For example, the tempo of the development of
not affect the course and severity of chronic rejection, it renal fibrosis in this model is more rapid than that typi-
was clearly associated with altered expression of TGF-b cally seen in humans with chronic rejection. Further-
within the grafts. In control allografts four weeks after more, in humans and in a number of animal models, graft
transplant, we found that intragraft TGF-b levels were arteriosclerosis with intimal proliferation is a cardinal
strikingly enhanced. Although there was a modest increase feature of chronic rejection. Although we identify many
in TGF-b protein in four-week MHC-deficient grafts rela- of the histopathological features of chronic rejection in
tive to isografts, the level of expression was notably less this mouse model, the vascular lesions, although severe,
do not precisely mimic the changes evident in humanthan allograft controls. This difference in TGF-b is espe-
renal allograft rejection. There is little evidence of arte-cially interesting given the putative relationship between
riosclerosis. Intimal proliferation is absent, and medialTGF-b and chronic rejection [7, 9, 10]. The mechanism
proliferation predominates. The lack of significant arte-underlying this difference in TGF-b expression in MHC-
riosclerosis and fibrointimal hyperplasia in these murinedeficient grafts is unclear. As reduced TGF-b levels were
kidney allografts may reflect the duration of the response.seen in both class I- and class II-deficient grafts, the cell
Our studies were performed at six weeks after trans-populations responsible for generating TGF-b do not
plantation, and the development of florid arteriosclerosisseem to result from a predominant CD41 or CD81-
is typically not seen until 12 to 16 weeks in rat kidney
mediated response. Rather, reduced TGF-b production
or heart grafts and as early as eight weeks in mouse
in the MHC-deficient grafts may reflect a reduction in cardiac allografts. In a previous study in mouse kidney
the overall intensity of the alloimmune response. Finally, allografts, vascular changes were not seen until 10 weeks,
because we have examined TGF-b expression at only and then only in large sized arteries [23]. Although the
two time points—four and six weeks—it is also possible reasons for the lack of characteristic vascular involve-
that the kinetics of TGF-b expression differ between the ment in this model are unclear, our studies suggest that
MHC-deficient and control animals. arteriosclerosis is not a prerequisite for the development
Transforming growth factor-b appears to have a role in of glomerulosclerosis and interstitial fibrosis in chronic
rejection.the development of progressive kidney injury associated
Fig. 4. Immunoperoxidase staining of transplanted kidneys for TGF-
b1 and TGF-b2 four weeks following transplantation. In isografts (a,
N 5 5), there was minimal staining. In allografts (b, N 5 5), there was
intense staining, particularly within the interstitium and around small
arteries, as shown. In class II2 allografts (c, N 5 3), this pattern was
similar, but staining was less intense (magnification 350). Reproduc-
tion of this figure in color was supported by a grant from Roche Pharma-
ceuticals.
Fig. 6. Immunoperoxidase staining for collagen type III in isografts
(a), control allografts (b), and MHC class II2 allografts (c) four weeks
following transplantation. Only trace amounts of collagen III are seen
in isografts compared with the increase in staining within the interstitium
of control allografts. In class II2 kidneys, collagen III staining was similar
to and nearly indistinguishable from control allografts (magnification
3100). Reproduction of this figure in color was supported by a grant
from Roche Pharmaceuticals.
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Fig. 5. Northern blot analysis for TGF-b in transplanted kidneys
four weeks following transplantation. Results were analyzed by
laser densitometry and normalized for b-actin expression. Com-
pared with isografts, enhanced expression for TGF-b1 and TGF-b3
was seen in control allografts and was modestly reduced in MHC
class II2 allografts.
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